Cisplatin Chemotherapy

Individuals with laryngeal cancer who stop smoking in the 2- to 4-week window between diagnosis and their first treatment can significantly improve their response to therapy, survival rates and quality of life.

Researchers at Brigham and Women’s Hospital developed a tool that predicts risks for moderate to severe kidney injury after treatment with the chemotherapy drug cisplatin.

Cisplatin chemotherapy may not reach its potential efficacy in individuals with head and neck cancer if they are exposed to secondhand smoke, according to results published in the International Journal of Molecular Sciences.

Survivors of testicular cancer often have undetected risk factors for cardiovascular disease that can lead to worse quality of life, according to data published in Journal of Clinical Oncology.

Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.

Since 2016, the National Cancer Institute said it has invested more than $1 billion in the Cancer Moonshot program, which has contributed to over 240 projects across more than 70 research initiatives.

Young children with cancer who received cisplatin chemotherapy had a higher incidence of cisplatin-induced hearing loss than older children, according to study results published in Cancer.

Patients with resectable stage IIIA non-small cell lung cancer treated with concurrent pembrolizumab plus neoadjuvant concurrent chemoradiation had high pathologic complete response rate at resection, however safety is a concern, according to data presented at the virtual ASCO Annual Meeting.